A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Abroad (travel likely)RecruitingPHASE1
Conditions
Neuroendocrine Carcinomas · Neuroendocrine Tumors · Carcinoma, Neuroendocrine · Carcinoma, Adrenocortical · Carcinoma, Adrenal Cortical
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (National Cancer Institute Medical Oncology) · NCIMO_Referrals@mail.nih.gov · 888-624-1937
Study leads
Jaydira Del Rivero, M.D.
Principal Investigator
National Cancer Institute (NCI)